Navigation Links
Paragon Bioservices Awarded $4.99 Million U.S. Army Contract to Assist with Ebola Vaccine Development
Date:10/21/2010

BALTIMORE, Oct. 21 /PRNewswire/ -- Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development and manufacturing of biologics, announced today that it has been awarded a $4.99 million contract to assist the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) in its vaccine development efforts.

The USAMRIID project involves process development and scale-up production of VLP-type vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses to support ongoing preclinical evaluation of efficacy, potency, and safety of these Filovirus vaccine candidates.  Utilizing their extensive VLP production and purification expertise, Paragon will develop a large-scale mammalian process suitable for future GMP manufacturing.

Ebola and Marburg viruses are a serious global health threat.  They cause hemorrhagic fever and have up to a 90 percent fatality rate in humans.  Currently, there are no vaccines or therapies available for these viruses.  They are commonly spread through blood and bodily fluids of infected patients who frequently succumb to hypovolemic shock.  Both viruses are potential agents of biological warfare or terrorism, since both are also infectious by aerosol.

Marco Chacon, Ph.D., CEO of Paragon Bioservices, commented, "As a scientist and a business man, it is extremely rewarding to be part of an effort that may improve public health, as well as enhance national preparedness.  Preventing the spread of Ebola and Marburg viruses is crucial to containing outbreaks and saving lives."

About Paragon BioservicesParagon Bioservices is a CMO focused on providing contract research, process development services and GMP manufacturing of biologics for Phase I/II clinical trials.  For more information about Paragon Bioservices, please visit www.paragonbioservices.com.

About USAMRIIDUSAMRIID, a division of the U.S. Army Medical Research and Materiel Command, plays a key role in both national defense and infectious disease research.  They are the lead medical research laboratory for the Department of Defense and the Biological Defense Research Program.  Their mission is essentially to conduct basic research on biological threats and to develop appropriate medical solutions—such as vaccines, drugs and diagnostics.Media Contacts:Tiberend Strategic Advisors, Inc.(212) 827-0020 Tamara Brighttbright@tiberendstrategicadvisors.comorClaire Sojdacsojda@tiberendstrategicadvisors.com
'/>"/>

SOURCE Paragon Bioservices
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Paragon Bioservices, Inc. Wins 2009 Lilly Global Supplier Award
2. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
3. ParagonRx Files with FDA REMS Panel Interim Analysis for Opioid Drugs Study
4. ParagonRx Sponsors Webinar-on-Demand By DSEC on Role of Drug Safety Officers
5. Avid Bioservices Expands Capabilities With Installation of Innovative Thermo Scientific HyClone Single-Use Bioreactor Systems
6. Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
7. Avid Bioservices Expands Executive Team as it Prepares for Continued Growth
8. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
9. Dr. Yong Shi awarded NSF grant
10. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
11. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
Breaking Biology News(10 mins):